肝硬化

Objective To understand the variation of serum lipid and apoprotein in posthepatitic cirrhosis and biliary cirrhosis.

要目的探讨病毒性肝炎肝硬化与胆汁性肝硬化之间的血脂、载脂蛋白变化及其临床。

Objective To explore the method of treatment for cirrhosis associated portal hypertension and hepatogenic diabetes.

要目的探讨肝硬化门静脉高压症合并肝源性糖尿病的疗方法。

Conclusion Saccharic metabolic disorder occurred easily in patient with hepatic cirrhosis，eventually develope into diabetes.

肝硬化患者应常规检测血糖避免漏诊。

Condlusion: Ganji composition has certain function on the prevention and cureeffect of partal hyperten sion associated with liver cirrhosis.

肝积合剂对肝硬化门脉高压症有一定的防作用。

Objective To explore the therapeutic effect of ascites superfilter concentration and reinfusion method on hepatic cirrhosis patients with refractory ascites.

目的探讨腹水超滤浓缩腹腔回输疗顽固性肝硬化腹水的效果。

Objective To study the clinical significance of urine Glycyl proline dipeptidyl aminopeptidase (GPDA) for diagnosis of earlyrenal injury in liver cirrhosis.

目的探讨应用尿甘氨酰脯氨酸二肽氨基肽酶(GPDA)诊断肝硬化早期肾损害的临床。

One patient with transversal injury of choledoch voluntarily left the hospital because of occurrence of extrahepatic obstructive biliary cirrhosis after the operations.

1胆总管横断伤因误诊多次手术,并发胆汁性肝硬化自动出院。

The fibrosis of liver not only causes chronic hepatitis, hypohepatia, and sequelae after cure, but also is the necessary process of hepatocirrhosis.

肝纤维化不仅造成慢性肝炎、肝功能异常和影响愈后，而且是诸多慢性肝病向肝硬化发展的必经阶段。

Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.

合并肝硬化的慢性丙肝（CHC）患者接受α干扰素包括派罗欣疗时存在肝功能失代偿和死亡风险。

Early diagnosis and treatment is of significance for preventing hepatic fibrosis and hepatic cirrhosis development as well as for improving life quality of hepatopath patients.

对肝纤维化进行早期诊断、早期疗，预防肝硬化的发生、发展，对肝病患者的生命质量具有重要的。

Objective To observe the effect and machanism of Xiaogu Granule (Granules for treating tympanites) plus ultrafiltration and reinfusion of ascites on refractory ascites resulted from hepatocirrhosis.

目的观察消臌颗粒配合腹水超滤浓缩回输疗顽固性肝硬化腹水的临床疗效并探讨其作用机制。